Christopher Estopinal, MD
Ophthalmology · Richmond, VANPI 1760778401
Payments from drug & device makers
Across 48 payments — averaging $26.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$248
- Glaukos Corporation$234
- Omeros Corporation$163
- Ocular Therapeutix, Inc.$142
- Sun Pharmaceutical Industries Inc.$123
- Oyster Point Pharma, Inc.$57
- plus $330 from 14 others
What the payments were for
- Food & beverage$1,296100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 8 | $248 |
| Glaukos Corporation | 4 | $234 |
| Omeros Corporation | 3 | $163 |
| Ocular Therapeutix, Inc. | 8 | $142 |
| Sun Pharmaceutical Industries Inc. | 6 | $123 |
| Oyster Point Pharma, Inc. | 2 | $57 |
| Thea Pharma Inc. | 2 | $45 |
| Notal Vision, Inc. | 2 | $45 |
| Rxsight Inc | 1 | $33 |
| AbbVie(2 entities) | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Harrow Eye, LLC | 1 | $21 |
| Biotissue Holdings Inc. | 1 | $20 |
| Dompe US, Inc. | 1 | $19 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| Amgen | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Tearlab Corp | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMIDRIA$125
How this compares
$1,296 in reported general payments places this provider in the 55th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 78 | $86,913 |
| XiidraLifitegrast | 29 | $47,525 |
| TyrvayaVarenicline Tartrate | 34 | $28,342 |
| CequaCyclosporine | 27 | $28,265 |
| Prednisolone Acetate | 415 | $18,278 |
| LumiganBimatoprost | 31 | $14,957 |
| Cyclosporine | 26 | $13,933 |
| MoxifloxacinMoxifloxacin Hcl | 258 | $6,401 |
| ValacyclovirValacyclovir Hcl | 126 | $4,264 |
| Latanoprost | 339 | $4,056 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $3,910 |
| LotemaxLoteprednol Etabonate | 12 | $3,627 |
| Travoprost | 16 | $3,335 |
| Loteprednol Etabonate | 26 | $2,907 |
| Timolol Maleate | 163 | $2,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $29 | $101,869109 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $57 | $28,34234 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $123 | $28,26527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Richmond
- Ali TabassianRichmond$2.1M
- Ethnie JonesRichmond$2M
- John O KeefeRichmond$44K
- Byron LaddRichmond$32K
- Thomas JenkinsRichmond$26K
- Ryan DeasyRichmond$19K
- Jessica RandolphRichmond$18K
- David JacobsRichmond$16K
- Nikisha RichardsRichmond$16K
- Kenneth PriceRichmond$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.